The global rosai-dorfman disease (RDD) therapeutics market is poised for significant growth, with projections indicating an increase from USD 431 Million in 2023 to USD 839.95 Million by 2033, reflecting a robust CAGR of 6.9% during the forecast period. This surge is attributed to the rising prevalence of RDD, an increasing demand for effective therapeutic …